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Background: Secukinumab has demonstrated significant and rapid
efficacy in the treatment of psoriasis in two phase 3 studies. We
present the first randomized, multicentre, double-blind, placebo
(PBO)-controlled phase III study to assess the efficacy and safety of
secukinumab in patients (pts) with PsA (FUTURE 1; NCT01392326).
Methods: 606 adults with active, moderate to severe PsA were
randomized to secukinumab or PBO. Pts on secukinumab received
10 mg/kg i.v. loading dose at baseline, week 2 and week 4, then either
75 mg s.c. (10 i.v.!75 s.c.) or 150 mg s.c. (10 i.v.!150 s.c.) every 4
weeks from week 8. PBO was given on the same schedules. Patients
naı¨ve to anti-TNF therapy (70%) and those intolerant of or
inadequate responders to anti-TNF therapy (TNF-IR; 30%), were
stratified across groups. Statistical analyses for the primary and
multiple secondary endpoints used non-responder imputation (binary
variables), mixed-effects repeated measures model (continuous
variables) and linear extrapolation (radiographic data), following a
pre-defined hierarchical hypothesis testing strategy to adjust for
multiplicity.
Results: Demographics and baseline characteristics were balanced
between groups. Both 10 i.v.!75 s.c. and 10 i.v.!150 s.c. demon-
strated significantly higher ACR20 responses vs PBO at week 24
(50.5% and 50.0% vs 17.3%, respectively; P< 0.0001 vs PBO). All pre-
specified secondary endpoints, including dactylitis, enthesitis, SF36-
PCS, HAQ-DI, DAS for 28 joints (DAS28)-CRP, ACR50, PASI 75, PASI
90 and mTSS score were achieved by week 24 and reached statistical
significance; active dose separated from PBO as early as week 1 for
ACR20, DAS28-CRP and HAQ-DI. Drug exposure levels were similar in
the secukinumab groups up to the primary endpoint due to i.v. loading.
Improvements in all primary and secondary endpoints were sustained
through week 52. At week 52, ACR 20/50/70 responses, using an
observed analysis, were 66.9%, 38.4% and 25.6% for 10 i.v.!75 s.c.
and 69.5%, 50.0% and 28.2% for 10 i.v.!150 s.c. In both TNF-naı¨ve
and TNF-IR groups, secukinumab demonstrated superiority at week
24 in ACR20/50/70, PASI 75/90, HAQ-DI, SF36-PCS, dactylitis and
enthesitis at both doses and the effect was maintained through week
52. Secukinumab significantly inhibited radiographic structural joint
damage at week 24 vs PBO. AEs at week 16: 60.4% (10 i.v.!75 s.c.),
64.9% (10 i.v.!150 s.c.) and 58.4% (PBO); non-fatal serious adverse
event rates: 2.5%, 4.5% and 5.0%, respectively. Mean, median and
maximum exposures: 438.5, 456.0 and 721 days; AE/non-fatal serious
adverse event rates: 78.1%/8.6% and 82.4%/12.9% in patients who
received secukinumab 75 mg s.c. or 150 mg s.c., respectively, at any
point in the study.
Conclusion: In this first phase 3 trial to evaluate highly selective IL-
17A inhibition in pts with PsA, secukinumab provided rapid, clinically
significant and sustained improvements in signs and symptoms, and
inhibited joint structural damage. Secukinumab was well tolerated
through 52 wks.
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